Sanofi/Regeneron's IO Springboard Libtayo Cleared For Skin Cancer
Executive Summary
In addition to skin cancer, the PD-1 inhibitor cemiplimab is being positioned for a range of other tumor types with Phase III studies ongoing in lung and cervical cancers.